| Literature DB >> 31665636 |
Linda Schadt1, Colin Sparano1, Nicole Angelika Schweiger1, Karina Silina1, Virginia Cecconi1, Giulia Lucchiari1, Hideo Yagita2, Emilien Guggisberg1, Sascha Saba1, Zuzana Nascakova3, Winfried Barchet4, Maries van den Broek5.
Abstract
Sensing of cytoplasmic DNA by cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) results in production of the dinucleotide cGAMP and consecutive activation of stimulator of interferon genes (STING) followed by production of type I interferon (IFN). Although cancer cells contain supra-normal concentrations of cytoplasmic DNA, they rarely produce type I IFN spontaneously. This suggests that defects in the DNA-sensing pathway may serve as an immune escape mechanism. We find that cancer cells produce cGAMP that is transferred via gap junctions to tumor-associated dendritic cells (DCs) and macrophages, which respond by producing type I IFN in situ. Cancer-cell-intrinsic expression of cGAS, but not STING, promotes infiltration by effector CD8+ T cells and consequently results in prolonged survival. Furthermore, cGAS-expressing cancers respond better to genotoxic treatments and immunotherapy. Thus, cancer-cell-derived cGAMP is crucial to protective anti-tumor CD8+ T cell immunity. Consequently, cancer-cell-intrinsic expression of cGAS determines tumor immunogenicity and makes tumors hot. These findings are relevant for genotoxic and immune therapies for cancer.Entities:
Keywords: CD8(+) T cells; STING; cGAMP; cGAS; cancer; chemotherapy; gap junctions; immunotherapy; radiotherapy; type I IFN
Mesh:
Substances:
Year: 2019 PMID: 31665636 DOI: 10.1016/j.celrep.2019.09.065
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423